October 01, 2016 2:20 PM ET


Company Overview of Tarveda Therapeutics, Inc.

Company Overview

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. The company offers Pentarins, which are miniaturized biologic drug conjugates that target, penetrate, and treat solid tumors. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. Tarveda Therapeutics, Inc. was founded in 2011 and is based in Watertown, Massachusetts.

134 Coolidge Avenue

Watertown, MA 02472

United States

Founded in 2011





Key Executives for Tarveda Therapeutics, Inc.

Interim Chairman, Chief Executive Officer and President
Age: 49
Founder, Director and Member of Scientific Advisory Board
Age: 67
Founder, Director and Member of Scientific Advisory Board
Age: 47
Founder and Chairman of Scientific Advisory Board
Chief Scientific Officer and President of Research & Development
Compensation as of Fiscal Year 2016.

Tarveda Therapeutics, Inc. Key Developments

Tarveda Therapeutics, Inc. Announces Management Appointments

Tarveda Therapeutics, Inc. announced the appointment of Leila Alland, M.D. to the position of Chief Medical Officer. Dr. Alland brings more than 15 years of pharmaceutical drug development experience with a focus on oncology including leadership roles in clinical development at AstraZeneca and Bristol-Myers Squibb. Dr. Alland has broad experience as a clinical leader developing both small and large molecule oncology products including Doxil, Pegintron, Tasigna, and Opdivo. Dr. Alland most recently served as Vice President and Head of Oncology Early Clinical Development at AstraZeneca where she was instrumental in building a new Oncology Early Clinical Development unit in Boston, MA, and Cambridge, UK. The company announced that Mary Simcox, Ph.D. has joined as Vice President of Biology. Dr. Simcox brings to Tarveda more than 10 years of experience in cancer cell biology and pharmaceutical drug discovery and development, including her most recent role as Director of Biology for FORMA Therapeutics as well as previous senior R&D roles at Roche in cancer signaling, preclinical angiogenesis and Avastin biomarkers.

Blend Therapeutics, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-12-2016 09:30 AM

Blend Therapeutics, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-12-2016 09:30 AM. Venue: Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco, CA 94102, United States.

Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

Blend Therapeutics, Inc. appointed Drew Fromkin as President and Chief Executive Officer and a member of the company’s Board of Directors. Mr. Fromkin previously served as President and Chief Executive Officer of Clinical Data, Inc. He is an accomplished, global healthcare leader with more than 25 years of experience leading private and public life sciences and healthcare services companies through all stages of growth, including product development and commercial operations. Mr. Fromkin takes on the role of CEO at a pivotal time when Blend is positioned to rapidly advance its novel pipeline of innovative anti-cancer therapeutics into human clinical trials in a variety of cancers. He will lead the company in its plans to file two Investigational New Drug (IND) applications with the U.S. Food and Drug Administration, respectively, in second quarter 2015 for its novel personalized cisplatin prodrug, BTP-114, and in early 2016 for its first targeted drug candidate from its proprietary Pentarin™ platform, BTP-277. BTP-114.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Private Placement
January 15, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tarveda Therapeutics, Inc., please visit www.tarveda.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.